Memory B cell responses induced by pneumococcal conjugate vaccine schedules with fewer doses: analysis of a randomised-controlled trial in Viet Nam

Darren Suryawijaya Ong, Thanh V. Phan, Beth Temple, Zheng Quan Toh, Cattram Duong Nguyen, Kien Vientrung, Hoang Van Anh Nguyen, Vo Trang Dai, Kathryn Bright, Hau Phuc Tran, Rachel Ann Higgins, Yin Bun Cheung, Thuong Nguyen, Kim Mulholland and Paul Vincent Licciardi ()
Additional contact information
Darren Suryawijaya Ong: Murdoch Children’s Research Institute
Thanh V. Phan: Pasteur Institute of Ho Chi Minh City
Beth Temple: Murdoch Children’s Research Institute
Zheng Quan Toh: Murdoch Children’s Research Institute
Cattram Duong Nguyen: Murdoch Children’s Research Institute
Kien Vientrung: Pasteur Institute of Ho Chi Minh City
Hoang Van Anh Nguyen: Pasteur Institute of Ho Chi Minh City
Vo Trang Dai: Pasteur Institute of Ho Chi Minh City
Kathryn Bright: Murdoch Children’s Research Institute
Hau Phuc Tran: Pasteur Institute of Ho Chi Minh City
Rachel Ann Higgins: Murdoch Children’s Research Institute
Yin Bun Cheung: Duke-NUS Medical School
Thuong Nguyen: Pasteur Institute of Ho Chi Minh City
Kim Mulholland: Murdoch Children’s Research Institute
Paul Vincent Licciardi: Murdoch Children’s Research Institute

Nature Communications, 2024, vol. 15, issue 1, 1-10

Abstract: Abstract The use of pneumococcal conjugate vaccine (PCV) schedules with fewer doses are being considered to reduce costs and improve access, particularly in low- and middle-income countries. While several studies have assessed their immunogenicity, there are limited data on their potential for long-term immune protection, as assessed by pneumococcal serotype-specific memory B cell (Bmem) responses. This current study reports secondary outcome data that aims to compare Bmem responses following reduced-dose (0 + 1 and 1 + 1) schedules of PCV10 and PCV13 in Vietnamese infants from our randomised-controlled trial (trial registration number NCT03098628). Following vaccination at 12 months of age, Bmem levels for most serotypes peaked seven days post-vaccination and were higher in magnitude for the 1 + 1 than 0 + 1 schedules and for PCV13 than PCV10. Furthermore, Bmem did not wane as rapidly as IgG levels by 24 months of age. Further studies are needed to assess the use of Bmem as markers of long-term protection against pneumococcal carriage and disease, which is crucial to generate data for immunisation program decision-making.

Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-024-51413-7 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-51413-7

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-51413-7

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().